Marco L. Lolli

Prof Marco L. Lolli is an internationally recognized expert in *Medicinal Chemistry* specialized in *hit-to-led* optimization process and the design of bioactive using innovative bioisosteric tools. By investigating the application as *bioisosteres* and expanding their synthetic accessibility of acidic **hydroxyazoles**, over the years he created a versatile tool effective in exploring the chemical space. This technology allowed the discovery of **MEDS433**, a potent Dihydroorotate Dehydrogenase (*h*DHODH) inhibitor in advance preclinical stage for Acute Myeloid Leukemia and antiSARS-CoV-2.

His major research interests in Drug Design are: *broad-spectrum antivirals* (SARS-CoV-2 and other CoVs), *cancer* (Leukemia, Breast and Prostatic cancer), *neglected diseases* (Malaria, Leishmaniasis, ….) and *Neurotransmission* (*Gaba* and *Glu*).

After a Master's degree in chemistry, he has been trained in prestigious national (*Istituto Ricerche Farmacologiche "Mario Negri", Bracco Industria Chimica s.p.a, Research and Development Division*) and foreigners (*College of Pharmacy, The Ohio State University, Columbus, OH, (USA), School of Pharmacy - University of Wisconsin at Madison, Madison (WI, USA)*) laboratories. Since 2022, he is **Associate Professor in Medicinal Chemistry** (03/D1) at the *Dept of Science and Drug Technology* of the University of Turin. In February 2022, he also obtained **National Scientific Qualification (ASN) as Full Professor in Medicinal Chemistry** (03/D1, February 1th, 2022 - February 1th, 2031).

He has been **Visiting Professor** in Eu (*Denmark, Sweden, UK*) and no-Eu countries (*Bolivia, India, US*) countries.

Since 2012, he has held key roles as PI, *MedChem Unit Coordinator* or *Scientific Lead*, in **15 competitive projects** (IT and European) raising around 3.2 million Euros in research funds. Inside them, he is playing the Pi role in the prestigious *Science for Peace and Security Programme 2022,* funded by NATO. To these funds must be added 1.63 million Euros acquired from Drug Discovery and Clinic s.r.l. where he holds the role of CEO. See www.medsynth.unito.it for details.

In order to move his best research to the *market*, he cofounded of **two SpinOffs** at UniTo:

- **Beenext s.r.l** (2013-2022, www.beenext.it) having the mission in introduce to the market innovative scientific glassware and offer educational support.
- **Drug Discovery and Clinic (DDC) s.r.l.** (2020 - present, www.DDCpharmaceutical.com) whose mission is to lead a new patented dihydroorotate dehydrogenase (*h*DHODH) inhibitor until human clinical trials for curing Acute Myeloid Leukemia (AML) and COVID-19.

Expertise: *Medicinal Chemistry, Drug Design, Synthetic Chemistry, Metabolism, Bioisosterism*.

Bibliometric indicators (upgraded June 2023):

Publications:	**64**
Patents:	**6**
Scopus:	Citations: 1296; H. Index:23
WOS,	Citations: 1242; H. Index: 23
ORCID iD:	https://orcid.org/0000-0002-3030-3163
Oral presentations	18 (+ over 100 other forms of meeting presentations)
Awards	6

Master / PhD teaching/Tutoring skills

Since 1999, he always played his educational roles (Master / PhD level) with great passion. At the present, he is in charge of two Courses (*Drug Analysis II* and *Drug Synthesis and Development Methodologies,* this latter at the Chemistry Dept of UniTO) involving almost 90 students and 190 h over two semesters. In recent years he had further refined his qualities as Advisor / Teacher, rationalizing them through the attendance of two UniTO courses, specifically dedicated to *advanced teaching techniques* enriched by the use of new technologies. He became skilled in training young scientist (**6** Post-Docs and more **90** Master students). Tutor panel of PhD course *in Pharmaceutical and Biomolecular Sciences* in the PhD *School of Natural Sciences and Innovative Technologies* at UniTO (**6** PhD students, in two occasions inside a *Double-Degree* PhD Agreement arranged between UniTO and the University of Copenhagen (DK)).